TNGX Q4 2024 Earnings — Tango Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TNGXTango Therapeutics, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-24.2% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$41M-993.7% margin

Net Income

-$38M-915.0% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-64.5%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$316M

Total Liabilities

$117M

Stockholders' Equity

$200M

Cash & Equivalents

$70M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$5M	-24.2%
Gross Profit	$4M	$5M	-24.2%
Operating Income	-$41M	-$35M	-16.8%
Net Income	-$38M	-$31M	-22.5%

Revenue Segments

Collaboration Revenue

$18M100%